Antineoplastic Combined Chemotherapy ProtocolsAntineoplastic AgentsDoxorubicinCyclophosphamideCombined Modality TherapyOsteosarcomaCisplatinDisease-Free SurvivalTreatment OutcomeVincristinePrognosisArteritisPrecursor Cell Lymphoblastic Leukemia-LymphomaHeart FailureRetrospective StudiesClinical ProtocolsTreatment FailureAntibiotics, AntineoplasticAntineoplastic Agents, PhytogenicEtoposideBreast NeoplasmsNeoplasmsSurvival AnalysisDrug Administration ScheduleNeoadjuvant TherapyAntineoplastic Agents, AlkylatingPaclitaxelAntimetabolites, AntineoplasticLung NeoplasmsMethotrexateSurvival RateTime FactorsNeoplasm StagingDrug Resistance, NeoplasmCarboplatinBleomycinVinblastineFollow-Up StudiesCell Line, TumorTaxoidsDose-Response Relationship, DrugIfosfamideCytarabineOrganoplatinum CompoundsInduction ChemotherapyDeoxycytidineApoptosisDrug Screening Assays, AntitumorProspective StudiesNeoplasm Recurrence, LocalAnthracyclinesClinical Trials as TopicOvarian NeoplasmsDaunorubicinNeoplasm MetastasisAdenocarcinomaCarmustineCarcinoma, Non-Small-Cell LungVomitingTumor Cells, CulturedSalvage TherapyNauseaCamptothecinDrug SynergismKidney Failure, ChronicLymphoma, Non-HodgkinCell SurvivalColorectal NeoplasmsNeutropeniaInfusions, IntravenousRadiotherapyMitomycinChemotherapy, Cancer, Regional PerfusionBrain NeoplasmsLomustineFailure to ThriveTransplantation, AutologousKaplan-Meier EstimateDacarbazineMelphalanBone NeoplasmsRandomized Controlled Trials as TopicTesticular NeoplasmsRadiotherapy, AdjuvantDisease ProgressionHodgkin DiseaseLeukopeniaLiver Failure, AcuteDrug EvaluationMitoxantroneRecurrenceLiver NeoplasmsXenograft Model Antitumor AssaysLeukemia P388Antibodies, Monoclonal, HumanizedRisk FactorsLymphomaAntineoplastic Protocols6-MercaptopurineCell Proliferation